What we will not prescribe
Compounds people ask us for constantly and we do not dispense. Six of these were recommended for the 503A bulks list by an FDA advisory committee in July 2026 — a recommendation, not a decision, and HHS has not acted on it. Rather than quietly leave them off the shelf, here is the evidence for each, the regulatory position, and exactly what would have to change.
BPC-157
The most requested compound in any gym, and the one we will not write. Here is the evidence, and here is exactly why not.
Not dispensedKPV
Sold for gut and skin inflammation. The research is oral delivery in mice with colitis; the product is an injection for joints.
Not dispensedTB-500
Sold as thymosin beta-4. It is a short fragment of it, and the human trials everyone cites were run on the full molecule.
Not dispensedMOTS-c
Encoded in mitochondrial DNA, discovered in 2015, sold for metabolism and endurance. Every product page points at one mouse study.
Not dispensedEpitalon
Sold for longevity and telomeres. The weakest evidence base here: one research group, one journal, largely twenty years ago, never replicated.
Not approved yetRetatrutide
The largest weight-loss numbers anyone has published, and nobody can legally sell it. Here is the trial data and the actual timeline.
Not dispensedSemax
The best human evidence of the six, and still not enough: Russian approval, Russian trials, not replicated under a Western regulator.